Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Proton Rahman

Showing results (211-220 of 260) with videos related to

Pageof 26
Sort By:
Arthritis Research & Therapy|February 12, 2024
Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trialsAtul Deodhar, Andrew Blauvelt, Mark Lebwohl, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 22, 2018
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor InhibitorsAtul Deodhar, Denis Poddubnyy, Cesar Pacheco-Tena, et al.
Musculoskeletal Care|December 10, 2024
Canadian Patients With Axial Spondyloarthritis Require Almost a Decade To Be Diagnosed Leading to Severe Functional Limitation. Results From the International Map of Axial Spondyloarthritis (IMAS)Proton Rahman, Marco Garrido-Cumbrera, Sherry Rohekar, et al.
JAMA Dermatology|July 9, 2025
Ixekizumab and Malignant Neoplasms: A Pooled Analysis of Data From 25 Randomized Clinical TrialsJoseph F Merola, Kim A Papp, Atul Deodhar, et al.
Rheumatology (Oxford, England)|June 29, 2022
Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritisLaura C Coates, Christopher T Ritchlin, Laure Gossec, et al.
Lancet (London, England)|July 3, 2015
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trialIain B McInnes, Philip J Mease, Bruce Kirkham, et al.
Advances in Therapy|August 10, 2022
The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 TrialJeffrey R Curtis, Iain B McInnes, Proton Rahman, et al.
Drug Safety|October 31, 2023
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic ArthritisBruce Strober, Laura C Coates, Mark G Lebwohl, et al.
BMJ Open|April 7, 2016
Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitisProton Rahman, Denis Choquette, William G Bensen, et al.
Plos Genetics|December 15, 2010
Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's diseasePatrick Danoy, Karena Pryce, Johanna Hadler, et al.
Pageof 26

Showing results (211-220 of 260) with videos related to

Sort By:
Pageof 26
Arthritis Research & Therapy|February 12, 2024
Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trialsAtul Deodhar, Andrew Blauvelt, Mark Lebwohl, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 22, 2018
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor InhibitorsAtul Deodhar, Denis Poddubnyy, Cesar Pacheco-Tena, et al.
Musculoskeletal Care|December 10, 2024
Canadian Patients With Axial Spondyloarthritis Require Almost a Decade To Be Diagnosed Leading to Severe Functional Limitation. Results From the International Map of Axial Spondyloarthritis (IMAS)Proton Rahman, Marco Garrido-Cumbrera, Sherry Rohekar, et al.
JAMA Dermatology|July 9, 2025
Ixekizumab and Malignant Neoplasms: A Pooled Analysis of Data From 25 Randomized Clinical TrialsJoseph F Merola, Kim A Papp, Atul Deodhar, et al.
Rheumatology (Oxford, England)|June 29, 2022
Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritisLaura C Coates, Christopher T Ritchlin, Laure Gossec, et al.
Lancet (London, England)|July 3, 2015
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trialIain B McInnes, Philip J Mease, Bruce Kirkham, et al.
Advances in Therapy|August 10, 2022
The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 TrialJeffrey R Curtis, Iain B McInnes, Proton Rahman, et al.
Drug Safety|October 31, 2023
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic ArthritisBruce Strober, Laura C Coates, Mark G Lebwohl, et al.
BMJ Open|April 7, 2016
Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitisProton Rahman, Denis Choquette, William G Bensen, et al.
Plos Genetics|December 15, 2010
Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's diseasePatrick Danoy, Karena Pryce, Johanna Hadler, et al.
Pageof 26